Search Results - "LIPSCOMB, John C"

Refine Results
  1. 1
  2. 2

    Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements by MAZUR, Christopher S, KENNEKE, John F, HESS-WILSON, Janet K, LIPSCOMB, John C

    Published in Drug metabolism and disposition (01-12-2010)
    “…The extent to which membrane-disrupting agents, such as alamethicin, may alter cofactor transport and influence in vitro kinetic measurements of…”
    Get full text
    Journal Article
  3. 3

    Putative Mechanisms of Environmental Chemical–Induced Steatosis by Kaiser, J. Phillip, Lipscomb, John C., Wesselkamper, Scott C.

    Published in International journal of toxicology (01-11-2012)
    “…Liver disease is a major health issue characterized by several pathological changes, with steatosis (fatty liver) representing a common initial step in its…”
    Get full text
    Journal Article
  4. 4

    Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice by Sasso, Alan F, Schlosser, Paul M, Kedderis, Gregory L, Genter, Mary Beth, Snawder, John E, Li, Zheng, Rieth, Susan, Lipscomb, John C

    Published in Toxicological sciences (01-02-2013)
    “…Physiologically based pharmacokinetic (PBPK) models are tools for interpreting toxicological data and extrapolating observations across species and route of…”
    Get full text
    Journal Article
  5. 5

    Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment by Meek, M.E. (Bette), Barton, Hugh A., Bessems, Jos G., Lipscomb, John C., Krishnan, Kannan

    Published in Regulatory toxicology and pharmacology (01-06-2013)
    “…•WHO IPCS has released a guidance document on PBPK modeling in risk assessment.•Communication between modelers and risk assessors is key to regulatory use of…”
    Get full text
    Journal Article
  6. 6

    Purpose-Driven Risk Assessment by Lipscomb, John C.

    Published in Toxicologic pathology (01-12-2019)
    “…Chemical exposures are routine; some are controlled, some are not. Whether an exposure should be controlled depends on the acceptability of the consequences of…”
    Get full text
    Journal Article
  7. 7

    Evaluating risk, exposure, and detection capabilities for chemical threats in water by Pfohl, Marisa, Silvestri, Erin, Lipscomb, John C., Snyder, Emily, Willison, Stuart

    “…The unexpected release of chemicals into the environment requires estimation of human health risks, followed by risk management decisions. When environmental…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Comparison of in vivo derived and scaled in vitro metabolic rate constants for several volatile organic compounds (VOCs) by Kenyon, Elaina M., Eklund, Christopher, Pegram, Rex A., Lipscomb, John C.

    Published in Toxicology in vitro (01-12-2020)
    “…Metabolic rate parameters estimation using in vitro data is necessary due to numbers of chemicals for which data are needed, trend towards minimizing…”
    Get full text
    Journal Article
  10. 10

    In vitro measurements of metabolism for application in pharmacokinetic modeling by Lipscomb, John C, Poet, Torka S

    Published in Pharmacology & therapeutics (Oxford) (01-04-2008)
    “…Human risk and exposure assessments require dosimetry information. Species-specific tissue dose response will be driven by physiological and biochemical…”
    Get full text
    Journal Article
  11. 11

    Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment by Meek, M.E. (Bette), Lipscomb, John C

    Published in Toxicology (Amsterdam) (05-06-2015)
    “…Abstract Testing strategies are anticipated to increasingly rely on in vitro data as a basis to characterize early steps or key events in toxicity at relevant…”
    Get full text
    Journal Article
  12. 12

    The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM) by Kenyon, Elaina M, Lipscomb, John C, Pegram, Rex A, George, Barbara J, Hines, Ronald N

    Published in Toxicological sciences (01-02-2019)
    “…Abstract Biotransformation rates extrapolated from in vitro data are used increasingly in human physiologically based pharmacokinetic (PBPK) models. This…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Identification of developmentally toxic drinking water disinfection byproducts and evaluation of data relevant to mode of action by Colman, Joan, Rice, Glenn E., Wright, J. Michael, Hunter, E. Sidney, Teuschler, Linda K., Lipscomb, John C., Hertzberg, Richard C., Simmons, Jane Ellen, Fransen, Margaret, Osier, Mark, Narotsky, Michael G.

    Published in Toxicology and applied pharmacology (15-07-2011)
    “…Reactions between chemicals used to disinfect drinking water and compounds present in source waters produce chemical mixtures containing hundreds of…”
    Get full text
    Journal Article Conference Proceeding
  16. 16

    Evaluation of physiologically based pharmacokinetic models for use in risk assessment by Chiu, Weihsueh A., Barton, Hugh A., DeWoskin, Robert S., Schlosser, Paul, Thompson, Chad M., Sonawane, Babasaheb, Lipscomb, John C., Krishnan, Kannan

    Published in Journal of applied toxicology (01-05-2007)
    “…Physiologically based pharmacokinetic (PBPK) models are sophisticated dosimetry models that offer great flexibility in modeling exposure scenarios for which…”
    Get full text
    Journal Article
  17. 17

    Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment by Lipscomb, John C, Haddad, Sami, Poet, Torka, Krishnan, Kannan

    “…Physiologically-based pharmacokinetic (PBPK) modeling offers a scientifically-sound framework for integrating mechanistic data on absorption, distribution,…”
    Get more information
    Journal Article
  18. 18

    The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM) by Kenyon, Elaina M., Eklund, Christopher, Lipscomb, John C., Pegram, Rex A.

    Published in Toxicology mechanisms and methods (12-10-2016)
    “…A rate for hepatic metabolism (V max ) determined in vitro must be scaled for in vivo use in a physiologically based pharmacokinetic (PBPK) model. This…”
    Get full text
    Journal Article
  19. 19

    Metabolism of Trichloroethylene by Lash, Lawrence H., Fisher, Jeffrey W., Lipscomb, John C., Parker, Jean C.

    Published in Environmental health perspectives (01-05-2000)
    “…A major focus in the study of metabolism and disposition of trichloroethylene (TCE) is to identify metabolites that can be used reliably to assess flux through…”
    Get full text
    Journal Article
  20. 20

    Correlating in vitro data to in vivo findings for risk assessment by Bale, Ambuja S, Kenyon, Elaina, Flynn, Thomas J, Lipscomb, John C, Mendrick, Donna L, Hartung, Thomas, Patton, Geoffrey W

    “…A special session at the Toxicology and Risk Assessment Conference in Cincinnati, OH, USA in May, 2012 presented approaches expanding upon current uses of in…”
    Get full text
    Journal Article